Hansa Medical
Advanced search
Log in
Press Room
Releases
Multimedia
About
Hansa Medical AB enters license agreement with Human Genome Sciences Inc.
9/6/2010 2:00 AM EST
Hansa Medical AB (NASDAQ OMX First North:HMED) today announced that they have entered a license agreement with Human Genome Sciences Inc. (NASDAQ:HGSI) regarding patents and patent applications around the drug target alpha-11.
The license agreement gives Hansa Medical an exclusive and global right to HGSIs all granted patents and pending patent applications regarding inventions around the alpha-11 integrin such as therapeutic anti-alpha-11 antibodies. Specific terms of the agreement were not disclosed.
“By uniting Hansa Medicals’ alpha-11 patent applications with the patents around alpha-11 developed by Human Genome Sciences, we create a strong patent portfolio for our anti-alpha-11 program. Integrating all intellectual property around the alpha-11 protein in one portfolio will further increase the commercial potential for this novel and innovative drug target” says Emanuel Björne, Chief Executive Officer of Hansa Medical.
Alpha-11 is a novel drug target for treatment of the...
Clinical research results with HMD-301 published in Clinical Infectious Diseases
9/28/2009 2:00 AM EST
The scientific journal Clinical Infectious Diseases (DOI: 10.1086/605563) has published clinical research results showing that elevated levels of the biomarker HBP,...
Interim report January 1 – June 30, 2009
7/30/2009 2:00 AM EST
Hansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammatory diseases. The company mainly pursues three lead projects: IdeS,...
Hansa Medical and Inverness Medical Innovations launch partnership agreement for the development of biopharmaceuticals to treat rheumatoid arthritis
6/22/2009 2:00 AM EST
Hansa Medical AB (NASDAQ OMX First North: HMED) and the US company Inverness Medical Innovations Inc. (NYSE: IMA) have initiated an exclusive and global partnership and license...
Hansa Medical and Axis-Shield enter development and license agreement regarding novel biomarker for severe sepsis
6/15/2009 2:00 AM EST
Hansa Medical AB (NASDAQ OMX First North: HMED) and Axis-Shield plc (LON: ASD) have entered an exclusive and worldwide agreement to develop and commercialise Hansa Medical’s...
Hansa Medical receives financing from VINNOVA for research project
5/7/2009 2:00 AM EST
Hansa Medical has received SEK 500,000 in financing from VINNOVA’s Forska&Väx (Research and Grow) program to implement a preliminary study in the framework of Hansa Medical’s TAME...
Press release from the 2009 Annual General Meeting of Hansa Medical AB
4/30/2009 2:00 AM EST
The following resolutions were passed at Hansa Medical’s Annual General Meeting held in Malmö on April 29, 2009:
The Meeting adopted the income statement, balance sheet,...
Hansa Medical’s Election Committee moves for re-election of the Board
4/15/2009 2:00 AM EST
At Hansa Medical’s Annual General Meeting on April 29, 2009, the company’s Election Committee will move for the re-election of the current Board members Bo Håkansson, Stina...
Annual Report 2008 (In Swedish)
4/5/2009 2:00 AM EST
The annual report for Hansa Medical 2008 (In Swedish) is available as PDF the 15th of April 2009 through www.hansamedical.com. A print version of the annual report can be ordered...
Hansa Medical divests research project
4/3/2009 2:00 AM EST
Hansa Medical has entered into an agreement with a limited liability company founded and controlled by Evy Lundgren-Åkerlund regarding the full divestment of the alpha-10 project.
Notice of the Annual General Meeting of Hansa Medical AB (publ)
3/31/2009 2:00 AM EST
The shareholders of Hansa Medical AB (publ) are hereby notified of the Annual General Meeting on Wednesday, April 29, 2009 at 6:00 p.m. at Malmö Börshus, Skeppsbron 2, Malmö. The...
Year-End Release 2008
2/10/2009 2:00 AM EST
Biotech company Hansa Medical develops biological pharmaceuticals for treatment of autoimmune diseases and transplantation rejection. The company is pursuing two development...
Hansa Medical changes certified adviser
11/24/2008 2:00 AM EST
As of December 1, 2008, Hansa Medical AB (publ) will change its certified adviser from Kaupthing Bank Sverige AB to Remium AB. The Hansa Medical share is traded on First North...
Interim report January 1 – June 30, 2008
8/21/2008 2:00 AM EST
Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company is pursuing four development projects: IdeS/EndoS, sepsis...
Hansa Medical redeems convertible loan – positive earnings effect of SEK 15.1 M
5/15/2008 2:00 AM EST
Hansa Medical has entered into an agreement covering the repayment of the convertible loan granted to the company by Biolin AB (publ) in connection with Hansa Medical’s spinoff...
Press release from the Annual General Meeting of Hansa Medical AB (publ) on May 7, 2008
5/8/2008 2:00 AM EST
At Hansa Medical’s Annual General Meeting in Malmö, Sweden on May 7, 2008, CEO Emanuel Björne presented the highlights of the company’s development projects during the past year...
Annual Report 2007 (In Swedish)
4/23/2008 2:00 AM EST
The annual report for Hansa Medical 2007 (In Swedish) is available as PDF April 23, 2008 through www.hansamedical.com. A print version of the annual report can be ordered through...
Notice of the Annual General Meeting of Hansa Medical AB (publ)
4/8/2008 2:00 AM EST
The shareholders of Hansa Medical AB (publ) are hereby notified of the Annual General Meeting on Wednesday, May 7, 2008 at 5:30 p.m. in the Auditorium of the Clinical Research...
Year-End Release 2007
2/28/2008 2:00 AM EST
Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company’s long-term goal is to bring new products to market through...
Hansa Medical acquires all assets in Cartela AB
1/15/2008 2:00 AM EST
Hansa Medical has broadened its project portfolio in the area of inflammatory diseases by acquiring all assets from Cartela i konkurs AB. Cartela has developed antibodies intended...
Chairman of the Board acquires shares
11/20/2007 2:00 AM EST
Through a holding company, Hansa Medical’s Chairman of the Board, Bo Håkansson, has increased his shareholding in Hansa Medical AB by 52,500 shares. Following the acquisition, Bo...
SEE ALL NEWS
Hansa Medical
RSS
Subscribe by Email
View more
CONTACT
Hansa Medical
Tweet
Media
more